---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-009437"
form_type: "8-K"
ticker: "ZVSA"
cik: "0001859007"
company_name: "ZyVersa Therapeutics, Inc."
filed_at: "2024-03-08T23:59:59+00:00"
generated_at: "2026-06-05T00:46:23.824975+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ZyVersa receives Nasdaq reprimand for July 2023 offering; proposes reverse stock split to cure bid price deficiency

## Summary
- Nasdaq staff determined July 2023 offering required stockholder approval; issued Letter of Reprimand, no further action.
- Company must cure bid price deficiency by May 3, 2024 to avoid delisting from Nasdaq.
- Special stockholders meeting on April 17, 2024 to vote on reverse stock split of 1:2 to 1:50.
- Company believes recent NLRP3 inhibitor data and upcoming phase 2a trial may raise stock price above $1.00, avoiding reverse split.
- Board retains right to abandon reverse stock split if bid price deficiency cured by other means.

## SEC filing metadata
- accession: 0001493152-24-009437
- form_type: 8-K
- ticker: ZVSA
- cik: 0001859007
- company_name: ZyVersa Therapeutics, Inc.
- filed_at: 2024-03-08T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859007/000149315224009437/0001493152-24-009437-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859007/000149315224009437/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-009437
- JSON: https://secwatch.observer/filing/0001493152-24-009437.json
- Plain text: https://secwatch.observer/filing/0001493152-24-009437.txt

## Key facts
- Listing & Compliance Notices
  ZyVersa Therapeutics, Inc. received a nasdaq deficiency notice notice regarding other (rules 5635(d), IM-5635-3, 5810(c)(4)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Rules: 5635(d), IM-5635-3, 5810(c)(4)
  source text: March 6, 2024, ZyVersa Therapeutics, Inc. (the “ Company ”) received a Letter of Reprimand (the “ Letter ”) from the staff (the “ Staff ”) of the Nasdaq Stock Market (the “ Nasdaq ”) in accordance with Nasdaq’s Listing Rule 5810(c)(4). The Staff has determined that the Company’s July 2023 best-efforts public offering of its common stock (“ Common Stock ”) and warrants to purchase shares of the Common Stock (the “ July 2023 Offering ”) did not qualify as a “Public Offering” as defined in Nasdaq’s Listing Rule IM-5635-3. Accordingly, because the July 2023 Offering was carried out at a price less
  evidence_url: https://www.sec.gov/Archives/edgar/data/1859007/000149315224009437/0001493152-24-009437-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.